Group items matching

in title, tags, annotations or url

The National Institute for Health and Care Excellence (NICE) has recommended faricimab as treatment option for adults with wet age-related macular degeneration or diabetic macular oedema. Thousands of people in England could benefit from the recommendation of a new drug that helps to treat two leading causes of sight loss and visual impairment. Faricimab is administered as an eye injection and is being recommended as an option for treating some adults with wet age-related macular degeneration (AMD) or with diabetic macular oedema (DMO). In the key clinical trials, aflibercept, another eye injection drug used to treat AMD and DMO, was administered every 8 weeks, while faricimab dosing, based on assessments of the disease activity, allowed for an interval of up to 16 weeks between doses, and was found to be equally effective. Up to 300,000 people in England with wet age-related macular degeneration (AMD) could be eligible to receive faricimab as part of their treatment alongside just over 28,000 people with diabetic macular oedema.

The National Institute for Health and Care Excellence (NICE) has recommended pembrolizumab in combination with chemotherapy (paclitaxel or nab-paclitaxel) which is said to benefit people with triple negative breast cancer. Clinical trial evidence shows that, compared with paclitaxel, pembrolizumab combination increases how long people have before their cancer gets worse and how long they live. NICE already recommends atezolizumab in combination with chemotherapy for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancer. Atezolizumab combination is recommended by NICE for people with IC equal to or greater than 1%. "This means that some people who can't have atezolizumab combination could be eligible for pembrolizumab combination," said NICE. NICE's independent appraisal committee also agreed that the pembrolizumab combination meets the higher cost-effectiveness threshold for life-extending treatments for people with a short life expectancy. Given by injection every 3 weeks, pembrolizumab (also called Keytruda and made by Merck Sharp and Dohme) is a type of immunotherapy that specifically targets triple negative breast cancer. It works by blocking the activity of a protein known as PD-L1 which is produced in larger amounts on cancerous cells than normal cells. By blocking PD-L1 it helps the person's own immune cells to attack the cancer.

In its first, the National Institute for Health and Care Excellence has recommended the use of long-acting injectable treatment for HIV-1 infection in adults, making around 13,000 people eligible for treatment with cabotegravir with rilpivirine in England. The new treatment aims to keep the number of virus particles in the blood so low that it cannot be detected or transmitted between people. Current treatment for HIV‑1 is lifelong antiretroviral tablets taken each day. Use of cabotegravir with rilpivirine is recommended when there is no evidence tosuspect viral resistance, and no previous failure of other anti-HIV-1 medicines. "Clinical trial results show that cabotegravir with rilpivirine is as effective as oralantiretrovirals at keeping the viral load low," NICE stated. Both are administered as two separate injections every two months, after an initial oral (tablet) lead-in period.

The Royal Pharmaceutical Society (RPS) has secured a contract with the National Institute for Health Research (NIHR) to deliver a suite of e-learning modules to help pharmacy professionals "become more research active". The new online resources - due to be launched next summer - are aimed at pharmacists and pharmacy technicians who may not have followed an academic career path or have had little or no experience of research delivery. The e-learning package will allow them to gain new skills so they feel more confident to engage with research and research opportunities. Nine modules are being developed covering how to transform ideas into a research project, find and evaluate evidence and choose the appropriate research methods whilst learning how to apply for research funding and deal with governance issues and publication.

The National Institute for Health and Care Excellence (NICE) has recommended icosapent ethyl also called Vazkepa manufactured by Amarin for adults who have cardiovascular disease with controlled LDL-C levels taking a statin. It's final draft guidance is expected to be available on the July 20. Nearly half a million people are expected to benefit from the first licensed treatment shown to reduce the risk of heart attacks and strokes in people with controlled low-density lipoprotein cholesterol (LDL-C - sometimes called "bad" cholesterol) who are taking a statin and who have raised levels of triglycerides. NICE said: "Clinical trial evidence suggests that for people with raised triglycerides who have LDL-C levels controlled by statins, and who have cardiovascular disease, icosapent ethyl reduces their risk of cardiovascular events by over a quarter compared with placebo. Helen Knight, interim director of medicines evaluation at NICE, said: "Icosapent ethyl is the first licensed treatment of its kind for people who are at risk of heart attacks and strokes despite well controlled LDL cholesterol because they have raised blood fats. And although lifestyle changes, including diet and exercise, can help to reduce their risk, these may not work for everyone.

The drug, 'durvalumab', can double the overall time someone can survive with an aggressive form of lung cancer from two-and-a-half to five years. It has been approved by the National Institute for Health and Care Excellence (NICE) and the NHS has sealed a deal with manufacturer AstraZeneca to begin rolling it out. The new treatment will be offered to more than 550 patients a year with advanced non-small-cell lung cancer (NSCLC) who have already undergone both chemotherapy and radiotherapy concurrently. NHS said: "The drug can stop the cancer from getting worse for more than two years - significantly longer than treatment with a combination of chemotherapy and radiotherapy, which can only hold the disease at bay for around six months. This increases overall survival time and gives patients more precious moments with their loved ones." Dame Cally Palmer, national cancer director for NHS England, said: "We are resolute in our ambition to fight the devastating effects of cancer and new pioneering treatments like durvalumab are a vital lifeline for people living with cancer - giving them more precious time with family and friends.

The National Institute of Health and Care Excellence has recommended that surgeons working in hospitals with limited or no access to a radiopharmacy department could now use Magtrace and Sentimag as an option to locate sentinel lymph nodes in people with breast cancer. The recommendation in draft NICE medical technology guidance could see a change in NHS standard care for the first time in years. The technology could also mitigate the reliance on radioactive isotope tracers shipped in from outside Great Britain. The magnetic liquid tracer - Magtrace - is a non-radioactive dark brown liquid. It is both a magnetic marker and a visual dye. The Magtrace is injected into the tissue around a tumour. The particles are then absorbed into the lymphatic system, following the route that cancer cells are most likely to take when they spread from the primary tumour and become trapped in sentinel lymph nodes. The Sentimag probe moves over the skin emitting sounds of different pitches as it passes over the Magtrace tracer, in a similar way to a metal detector locating metal in the ground. The nodes often appear dark brown or black in colour, which also helps with identification.

Many are well informed about different diseases that involve oral cavities. Fortunately, several medications assist in treating these diseases. Dentists or dental professionals prescribe drugs for dental care, depending on the issue. Specific medications are offered to prevent or treat infection, reduce anxiety, minimize pain and inflammation, treat bacterial infections, teeth cleaning or whitening, and many others. Overall, this article will get you acquainted with some types of medications dental professionals use in caring for their patient's teeth. If you want to know them, then read them on. 1. Conscious Sedation Drugs Many individuals experience anxiety when visiting a dentist. As such, a dentist may apply conscious sedation to ease such feelings. Conscious sedation is part of sedation dentistry in which a dentist alleviates dental anxiety by using sedative medications. The National Institutes of Health stated that you'll still be awake through conscious sedation. However, you'll become more unmindful of the dental procedure. Also, you may forget what occurred afterward. Note that conscious sedation differs from general anesthesia, which assists in making you wholly unconscious, and dentists generally employ this for lengthy dental procedures.

The National Institute for Health and Care Excellence (NICE) has recommended abemaciclib also called Verzenios, made by Eli Lilly, for people with hormone receptor-positive, HER2-negative, node-positive early breast cancer at high risk of recurrence who have had surgery to remove their tumour. The clinical trial result showed that people having abemaciclib with hormone therapy had a more than 30 per cent better chance of their cancer not coming back following surgery compared with people having hormone therapy alone. Helen Knight, interim director of medicines evaluation at NICE, said: "Today's positive draft recommendation, which comes less than a month after abemaciclib received its licence, is fantastic news. The fact that we have been able to produce draft recommendations so quickly is testament to the success of our ambition to support patient access to clinically and cost effective treatments as early as possible. "Until now there have been no targeted treatments for people with this type of breast cancer. Abemaciclib with hormone therapy represents a significant improvement in how it is treated because being able to have a targeted treatment earlier after surgery will increase the chance of curing the disease and reduce the likelihood of developing incurable advanced disease."

The National Institute for Health and Care Excellence (NICE) has issued draft guidance on 'Evusheld' which is not recommended for vulnerable adult with high risk of severe Covid-19 on Thursday (16 February). The draft guidance is open for public consultation until 9 March 2023. The committee will consider any comments received at a meeting currently due to take place on 4 April 2023. It comes after last month's decision by the US drug regulator to withdraw its emergency use authorisation for Evusheld as a preventative treatment for Covid-19, which said there was insufficient evidence that Evusheld is effective against the dominant variants of Covid-19 in the US. NICE's independent appraisal committee has reached the same conclusion having considered evidence which shows Evusheld is unlikely to prevent infection with most of the variants circulating in the UK now and in the near future. It has also announced that it is developing a new review process to update recommendations on the cost-effectiveness of Covid-19 treatments so they can be made available more quickly to patients if they show promise against new variants and are found to be cost-effective.

The National Institute for Health and Care Excellence (NICE) has recommended elosulfase alfa for routine use in the NHS for the treatment of mucopolysaccharidosis type 4A (also known as MPS 4A and Morquio A syndrome). Elosulfase alfa, also called Vimizin and made by BioMarin, becomes the first disease modifying treatment recommended by NICE for routine NHS use for people with this rare, severely life-limiting condition. NICE's final draft guidance follows the collection of 'real-world' data from 69 people who received NHS-funded treatment since 2015 as part of a managed access agreement. Clinical trial evidence and data collected as part of the managed access agreement, along with expert clinical opinion, shows some long-term benefits with elosulfase alfa treatment which suggest it slows progression of MPS 4A.

The National Institute for Health and Care Excellence (NICE)'s independent committee has called for more research to ensure liposuction for treatment of chronic lipoedema is safe and effective enough for use on the NHS. Lipoedema is more prevalent in women and very rarely affects men. It is characterised by an abnormal, usually symmetrical, accumulation of fat in the legs, hips, buttocks, and occasionally arms. It is a separate condition to obesity and lymphoedema. The cause of lipoedema is unknown, but hormonal changes, weight gain and genetics are thought to be involved. The size and shape of legs, and the resultant mobility issues and pain, can have a profoundly negative effect on quality of life, and physical and mental health. The interventional procedures advisory committee reviewed evidence from several sources, including eight before-and-after studies. The committee was informed that several different liposuction techniques are used and that they may have different safety and efficacy profiles.

Type 1 diabetes patients can monitor their glucose with the newly introduced flash glucose monitors by the NHS. The wearable gadgets with the size of a £2 coin, have a sensor that easily sits on the arm, allowing patients to check their glucose levels with a one-second scan. Eligible patients are currently able to access the monitors on prescription from their local GP or diabetes team, helping them to better manage their blood sugar levels. Everyone living with type 1 diabetes will be eligible for lifechanging flash glucose monitors on the NHS. The NHS Long Term Plan has already helped almost three in five people with Type 1 diabetes to access the monitors that allow people to check their glucose levels more easily and regularly. The change, confirmed today by the National Institute for Health and Care Excellence (NICE), means that everyone in England with the condition will be able to benefit from the convenient technology.

The current structure of global incentives to develop new antibiotics is insufficient and requires urgent resolution revealed a new report 'Incentivising new antibiotics' by the Office of Health Economics (OHE). OHE analysis demonstrates that on a global level, it is estimated that an effective 10-year incentive would require £3.5bn ($4.2bn) to adequately cover the entire research and development process for a new antibiotic. The report considers how health systems in the UK and around the world can stimulate the research and development (R&D) of new antibiotics. In 2020, the National Institute for Health and Care Excellence (NICE) and NHS England initiated an Antimicrobial Resistance pilot with the aim of incentivising pharmaceutical companies to develop new antibiotics by addressing the issues associated with reimbursement, which historically has deterred companies from pursuing AMR research.

The National Institute for Health and Care Excellence (NICE) has recommended Enhertu for people with advance breast cancer. "There is not enough evidence yet to show how much longer people live with Enhertu compared with trastuzumab emtansine because the clinical trial is still ongoing. This means the cost-effectiveness estimates are highly uncertain and Enhertu cannot be recommended for routine use in the NHS," said NICE. The independent appraisal committee concluded that Enhertu could be cost-effective if further evidence from the ongoing trial and from NHS practice can show how much longer people live with treatment. Helen Knight, director of medicines evaluation at NICE, said: "Today's draft guidance is good news for people with this type of advanced breast cancer, who often experience severe and debilitating symptoms.

Genomic sequencing allowed the world to track new coronavirus variants throughout the pandemic. Now British researchers plan to use it to better understand a host of other respiratory pathogens, from influenza to respiratory syncytial virus (RSV). The work is aimed at shedding more light on known threats and, potentially, emerging ones, the team at the Wellcome Sanger Institute, working with the UK Health Security Agency, said. The world has never had access to the kind of real-time information for these viruses that scientists obtained on SARS-CoV-2 through sequencing millions of genomes, Ewan Harrison, head of the new Respiratory Virus and Microbiome Initiative, told reporters on Monday. That includes granular detail on how they transmit as well as how they evolve in the face of the human immune response. "We hope that by expanding our ability to sequence these viruses routinely, we can build upon the work that's going on COVID, and hopefully supercharge research efforts to understand the transmission of these viruses, but also to help develop new treatments and vaccines," Harrison said.

Discover unparalleled healthcare services at Kailash Deepak Hospital, the leading medical institution in East Delhi. As the best private hospital in East Delhi, we are committed to delivering superior medical care with compassion and expertise. Our state-of-the-art facilities and experienced medical team ensure comprehensive treatment across various specialties. Trust Kailash Deepak Hospital for your healthcare needs in Delhi.

It isn't the hardest thing to find the right physiotherapist to treat you, but like many other professions, especially in health, physiotherapy has a number of different areas of expertise that are governed by strict and high standards of service. Physiotherapists have to be well educated and officially registered in order to practice. Identifying which therapist is able to provide the treatment for your specific needs and requires more than just picking up a phone book, or selecting the first site that pops up on google. Here's a list of what to look for when selecting a therapist as well as when to look for one. What to Look for Check their qualifications As is the case with any healthcare practitioner, it is important that your physiotherapist is fully qualified and accredited. It is required by law that they complete a degree at an approved educational institution, and are registered with the Physiotherapy Board. The board is responsible for keeping professional standards up to where they need to be, and for making sure that the Code of Practice is upheld.

Patients can obtain the Manipal Hospital Delhi contact number as it represents a leading multi-specialty healthcare institution offering top-notch medical services.

NHS England's decision to forgo commissioning puberty suppressing hormones (PSH) for children and young people, citing insufficient evidence of their safety and clinical effectiveness, follows a comprehensive review conducted by the National Institute for Health and Care Excellence (NICE) in 2020. The clinical report underscores that "PSH treatment options will not be part of routine commissioning" for people under the age of 18 in England grappling with gender incongruence or dysphoria. The NHS England review analysed nine observational studies on Gonadotrophin Releasing Hormone Analogues (GnRHa) and found no statistically significant difference in gender dysphoria, mental health, body image, and psychosocial functioning among children and adolescents treated with GnRHa. Duncan Rudkin, chief executive of the General Pharmaceutical Council (GPhC), acknowledged the challenges faced by pharmacy professionals regarding prescriptions for puberty suppressing hormones, stating: